Biotest activities against coronavirus

A global industry addresses global challenges related to covid-19: A PPTA initiative

Leaders of the plasma-processing industry express their appreciation and gratitude for plasma donors and their commitment to providing lifesaving plasma for patients around the world.
An initiative of  the Plasma Protein Therapeutics Association






Biotest research activities against the coronavirus

In this video Dr. Jörg Schüttrumpf, Head of Research & Development, explains very clearly how Biotest can use its new products in the field of coronavirus and what potential they offer for the company.


Press releases about coronavirus


06.04.2020 - Biotest produces life-saving medicine derived from plasma from healed COVID-19 patients and participates in a cross-industry initiative
PDF, 102 KB
[ Download ]


Biotest is developing with Trimodulin a COVID-19 therapy for patients with a severe course of the disease
PDF, 105 KB
[ Download ]

Corona virus information - No negative effects for Biotest

Our handling of the coronavirus

At Biotest, the safety and well-being of our employees, our customers and the patients who need our products is always our priority. We recognize the important role we play in limiting the spread of the COVID-19 infection and in helping safeguard public health. We are working closely with our customers to ensure the continuity of their businesses and, ultimately, provide stable supplies of medicines to help protect patients’ lives. .

We are in continuous communication with our employees reminding them about the importance of good hygiene, providing them with health education and support whenever needed. We have suspended all international business travel and limited domestic travel to essential meetings only. Wherever feasible, we are transitioning to virtual meetings and providing remote-work solutions. Employees who feel ill have been told to not report to work, likewise if a member of their household has a fever, respiratory condition or flu-like symptoms. Specific quarantine and communication procedures are in place should an employee be diagnosed with COVID-19 or is asked to self-isolate by a public health authority.

To date, we have managed to maintain all of our processes. Of course, this is only a snapshot and there is unfortunately no guarantee that it will stay that way. However, we assure you that Biotest AG will do everything in its power to continue to ensure patient care with life-saving medication.

Please understand that in the current exceptional situation we would like to refrain from replying to individual questionnaires or concerns that you have put forward In case you have further questions, please feel free to contact Biotest’s spokesman Dirk Neumueller, at +49 6103 801-269.

Notice concerning diagnostic Covid-19 tests

  • Biotest AG does not offer any diagnostic Covid-19 tests for sale
  • The use of the trademark 'Biotest' by Hangzhou Biotest Biotech Co. (HBBCL) in connection with Covid-19 quick tests occurs without our consent
  • HBBCL is not part of the Biotest or CREAT groups and has no connection to Biotest AG
  • Biotest AG has initiated measures to defend its trademark rights